As nations throughout the world race to develop a vaccine for the novel coronavirus, Indian pharmaceutical firm Strides is all set to take a look at favipiravir drug, which is touted as a possible remedy for the COVID-19. The firm has already acquired approval from the Drug Controller General of India to begin scientific trials of the treatment. For the uninitiated, Japan had already accredited this antiviral drug for the remedy of influenza in 2014.
According to a analysis paper revealed in PubMed.gov, Favipiravir, which is being touted as the potential remedy for COVID-19 is an antiviral agent and exhibits anti-viral actions in opposition to different RNA viruses similar to arenaviruses, bunyaviruses and filoviruses. It additional states that these distinctive anti-viral profiles will make favipiravir a doubtlessly promising drug for particularly untreatable RNA viral infections.
In addition to the Bengaluru-based Strides Pharma, one other Indian agency, Glenmark is additionally testing the efficacy of Favipiravir drug and is conducting part three scientific trials for the identical.